Saturday 17 October 2026 Export AKTX’s income statement to Excel — free account

Akari Therapeutics PLC

In the quarter to June 2026, EPS fell 60.3%, free cash flow grew 4.51% and total debt fell 1.00%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

8.18 0.66 −7.47%

Follow AKTX

Alert me

Market cap: $15.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.87%

Capital & Financial Ratios $m

Market Cap 15.47

Revenue —

Net Income (30.96)

Free Cash Flow (10.76)

Net Debt (7.06)

Current Ratio 0.60

Debt/Equity 0.04

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.79

Past 5Y EPS Growth —

This Y EPS Growth 52.32%

Next Y EPS Growth 44.32%

Next Y revenue growth —

Next 5Y EPS Growth 46.65%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 8.84%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	3	5	8
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	0	0	1
	4	3	5	8

	2023	2024	2025	Q'26
Payables	2	12	9	9
ST’ Debt	—	1	1	1
Other	1	1	0	0
	5	20	12	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(5.28%)	24.73%	151.02%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(2)	(3)	(2)	(3)	(11)
’24	(4)	(5)	(1)	(2)	(13)
’23	(5)	(5)	(2)	(4)	(16)
’22	(5)	(9)	—	—	(22)
’21	(7)	(5)	(2)	(5)	(19)
’20	(8)	(4)	(1)	(4)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(3)	—	—	—
’25	(2)	(3)	(2)	(3)	(11)
’24	(4)	(5)	(1)	(2)	(13)
’23	(5)	(5)	(2)	(4)	(16)
’22	(5)	(9)	—	—	(22)
’21	(7)	(5)	(2)	(5)	(19)
’20	(8)	(4)	(1)	(4)	(17)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(9.74)	(2.68)	—	—	—
’25	(5.43)	(1.67)	(7.84)	(5.61)	(20.55)
’24	(33.10)	(32.10)	(9.50)	0.00	(66.28)
’23	10.71	(0.68)	(22.70)	(38.17)	(81.79)
’22	(80.00)	(80.00)	—	—	(224.00)
’21	(120.00)	(88.00)	(24.00)	(96.00)	(328.00)
’20	(104.00)	(224.00)	21.58	(176.00)	(432.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5,368.00	2,546.40	1,248.00	1,272.00	696.00	1,056.00	304.80	106.00	36.00	8.72	Analyst estimates 2026–2028 Powerpack
	High	15,802.40	17,760.00	3,600.00	7,360.00	2,232.00	3,368.00	1,288.00	440.00	176.00	69.20
People
People	Employees	15	17	13	10	9	9	15	12	8	6
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(18)	(35)	(16)	(17)	(17)	(17)	(18)	(10)	(20)	(18)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(18)	(35)	(16)	(17)	(17)	(17)	(18)	(10)	(20)	(17)
	Depreciation	0	0	0	0	0	0	0	0	0	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(1,232.30)	(2,270.46)	(855.25)	(744.00)	(432.00)	(328.00)	(224.00)	(81.79)	(66.28)	(20.55)
	Cash flow	(1,675.14)	(2,025.56)	(1,169.96)	(564.12)	(429.12)	(350.96)	(275.34)	(134.25)	(42.04)	(12.56)
	Capex	(3.73)	(2.37)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(1,678.86)	(2,027.92)	(1,169.96)	(564.12)	(429.12)	(350.96)	(275.34)	(134.25)	(42.04)	(12.56)
	Book value	2,319.90	1,099.62	161.21	0.33	237.58	103.44	22.93	(1.87)	74.44	33.66
	Shares, m	0	0	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(25)	(32)	(23)	(13)	(17)	(19)	(22)	(16)	(13)	(11)
	Capex	0	0	—	—	—	—	—	—	—	—
	Free cash flow	(25)	(32)	(23)	(13)	(17)	(19)	(22)	(16)	(13)	(11)
Balance, $m
Balance, $m	Working capital	34	17	3	0	9	6	2	0	(17)	(7)
	Total debt	—	—	2	3	—	—	—	—	1	1
	Net debt	(44)	(28)	(4)	(3)	(14)	(9)	(13)	(4)	(2)	(5)
	Shareholders’ equity	34	17	3	0	9	6	2	0	22	28
Returns, %
Returns, %	ROA	(31.34)	(94.49)	(88.82)	(232.21)	(162.03)	(132.74)	(139.31)	(110.06)	(72.08)	(35.14)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(66.73)	(45.48)
	ROE	(43.81)	(138.13)	(162.51)	(1,080.27)	(363.75)	(233.27)	(483.23)	(1,281.43)	(179.92)	(68.43)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PBM Psyence Biomedical Ltd.	$16.5M	0.2×	—	—	n/m	−707.20% (below 0%: shrinking)	—	0.00%	Compare
TCRX TScan Therapeutics, Inc.	$16.2M	— (loss-making)	— (loss-making)	−65.83% (below 0%: shrinking)	n/m	+18.95% (above 0%: growing)	100.00%	(2,901.33%)	Compare
AKTX Akari Therapeutics PLC	$15.5M	— (loss-making)	—	—	n/m	+4.51% (above 0%: growing)	0.00%	0.00%
VAXX Vaxxinity, Inc.	$15.5M	— (loss-making)	— (loss-making)	−100.23% (below 0%: shrinking)	n/m	+17.00% (above 0%: growing)	0.00%	0.00%	Compare
MRKR MARKER THERAPEUTICS, INC.	$15.3M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	−97.84% (below 0%: shrinking)	100.00%	0.00%	Compare
NCEL NewcelX Ltd.	$15.3M	— (loss-making)	—	—	n/m	−87.71% (below 0%: shrinking)	0.00%	—	Compare
GTBP GT Biopharma, Inc.	$15.2M	— (loss-making)	—	−100.00% (below 0%: shrinking)	n/m	−41.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DARE Dare Bioscience, Inc.	$14.6M	— (loss-making)	— (loss-making)	+984.43% (above 0%: growing)	n/m	−30.23% (below 0%: shrinking)	(70.56%)	(1,582.93%)	Compare
ADAPY Adaptimmune Therapeutics PLC	$14.6M	— (loss-making)	— (loss-making)	−89.33% (below 0%: shrinking)	n/m	−174.72% (below 0%: shrinking)	81.71%	(221.45%)	Compare
Median of peers	$15.3M	—	—	−77.58%	—	−64.52%	0.00%	0.00%

All 614 Biotechnology stocks →

Akari Therapeutics PLC (AKTX) key facts

Akari Therapeutics PLC (AKTX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, AKTX traded at $8.18, a market capitalization of $15.5 million.
Return on equity was −68.4% and debt-to-equity 0.04.

Source: company filings (standardised) and stockrow calculations.